The Headache Inducing Effects of Cilostazol on Migraine Patients

Not Applicable

Completed

• Conditions: Migraine
• Interventions: Drug: Cilostazol; Drug: Placebo

• Registration Number: NCT01841827
• Lead Sponsor: Danish Headache Center

Brief Summary

We will use Cilostazol as a tool to investigate its headache inducing effects in migraine patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-04
• Study First Submitted: 2013-04-20
• Study First Submitted QC: 2013-04-26
• Study First Posted: 2013-04-29
• Primary Completion: 2013-06
• Study Completion: 2013-06
• Status Verified: 2014-06
• Last Update Submitted: 2014-06-05
• Last Update Posted: 2014-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Diagnosed with migraine without aura according to the IHS criteria from 2004.
• Healthy besides migraine

Exclusion Criteria

• Tension-type headache more than 3 days per month
• Other types of primary headaches
• Pregnancy
• History of vascular diseases or psychiatric diseases.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Cilostazol	Cilostazol	Capsule of Cilostazol 200 mg are taken orally on each study day
Placebo	Placebo	A capsule of placebo containing starch are taken orally on each study day.

Primary Outcome Measures

Name	Time	Method
The incidens of headache or migraine after adminstration of Cilostazol in migraine patients compared to placebo.	Outcome measure will be done within 3 month. Final data will be presented within 6 months	Rectruitment of 14 patients will be done during April and May. Experiments will be carried out in May and June. Each experiment day takes 1½ hour. Data analysis will be done in June and July. Final data will be presented within 6 months.

Trial Locations

Locations (1)

Danish Headache Center & Department of Neurology; 🇩🇰 Copenhagen, Glostrup, Denmark